BRISTOL MYERS SQUIBB CO
BMY · XNYSCIK 14272fmd_0R26GG1CQ776AQQF2C5DXQWB5VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 19,427 | 20,776 | 22,561 | 26,145 | 42,518 | 46,385 | 46,159 | 45,006 | 48,300 | 48,194 |
| Cost of revenue | 4,969 | 6,014 | 6,467 | 8,078 | 11,773 | 9,940 | 10,137 | 10,693 | 13,968 | 13,936 |
| Gross profit | 14,481 | 14,682 | 16,094 | 18,067 | 30,745 | 36,445 | 36,022 | 34,313 | 34,332 | 34,258 |
| Realized investment gains (losses) | – | – | – | – | 1,228 | 745 | (801) | (160) | 16 | 280 |
| Research and development | 5,012 | 6,468 | 6,332 | 6,148 | 10,048 | 10,195 | 9,509 | 9,299 | 11,159 | 9,951 |
| Selling, general and administrative | 4,979 | 4,751 | 4,551 | 4,871 | 7,661 | 7,690 | 7,814 | 7,772 | 8,414 | 7,267 |
| Interest expense | 167 | 196 | 183 | 656 | 1,420 | 1,334 | 1,232 | 1,166 | 1,947 | 1,891 |
| Interest and investment income | 97 | 126 | 173 | 464 | 121 | 39 | 171 | 449 | 478 | 586 |
| Other non-operating income (expense) | 1,448 | 1,685 | 854 | (938) | 2,314 | 720 | (576) | 1,158 | (893) | (674) |
| Income before taxes | 5,915 | 5,131 | 5,968 | 4,975 | (6,871) | 8,098 | 7,713 | 8,440 | (8,379) | 9,328 |
| Income tax expense | 1,408 | 4,156 | 1,021 | 1,515 | 2,124 | 1,084 | 1,368 | 400 | 554 | 2,272 |
| Net income from continuing operations | 4,507 | 975 | 4,947 | 3,460 | (8,995) | 7,014 | 6,345 | 8,040 | (8,933) | 7,056 |
| Net income | 4,457 | 1,007 | 4,920 | 3,439 | (9,015) | 6,994 | 6,327 | 8,025 | (8,948) | 7,054 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |